Hirata, Katsuya
Nambara, Toshihiko
Kawatani, Keiji
Nawa, Nobutoshi
Yoshimatsu, Hidetaka
Kusakabe, Haruna
Banno, Kimihiko
Nishimura, Ken
Ohtaka, Manami
Nakanishi, Mahito
Taniguchi, Hidetoshi
Arahori, Hitomi
Wada, Kazuko
Ozono, Keiichi
Kitabatake, Yasuji
Funding for this research was provided by:
Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (JP19bm0804009)
JSPS KAKENHI (JP13390324)
Article History
Received: 24 December 2019
Accepted: 27 July 2020
First Online: 20 August 2020
Competing interests
: The authors have read the journal’s policy and have the following competing interests. Dr. Mahito Nakanishi is the founder and chief technology officer of Tokiwa-Bio, Inc. Ms. Manami Ohtaka is an employee of Tokiwa-Bio, Inc. The method to generate iPS cells with the SeVdp vector installing reprogramming genes is protected by the following patents: JP 4936482, JP 5633075, JP 5963309, US 9145564, US 8496941 B2, US 9365866 B2, EP 2434012, and EP 2639297. This does not alter our adherence to all the <i>Scientific Reports</i> policies on sharing data and materials. All other authors have no conflict of interest to declare.